Literature DB >> 10026781

Vasopressin receptors. A historical survey.

S Jard1.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 10026781

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  11 in total

1.  Hypophysectomy and neurointermediate pituitary lobectomy decrease humoral immune responses to T-independent and T-dependent antigens.

Authors:  A Quintanar-Stephano; E Abarca-Rojano; R A Jarillo-Luna; V Rivera-Aguilar; J Ventura-Juárez; I Berczi; K Kovacs; R Campos-Rodríguez
Journal:  J Physiol Biochem       Date:  2010-04-21       Impact factor: 4.158

2.  Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist.

Authors:  Cristiana Griffante; Andrew Green; Ornella Curcuruto; Carl P Haslam; Bryony A Dickinson; Roberto Arban
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

Review 3.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  Conformation and dynamics of 8-Arg-vasopressin in solution.

Authors:  Elke Haensele; Lee Banting; David C Whitley; Timothy Clark
Journal:  J Mol Model       Date:  2014-11-06       Impact factor: 1.810

5.  Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia.

Authors:  Balázs Mayer; Krisztián Németh; Miklós Krepuska; Vamsee D Myneni; Dragan Maric; John F Tisdale; Matthew M Hsieh; Naoya Uchida; Heon-Jin Lee; Michael J Nemeth; Kenn Holmbeck; Constance Tom Noguchi; Heather Rogers; Soumyadeep Dey; Arne Hansen; Jeffrey Hong; Ian Chow; Sharon Key; Ildikó Szalayova; Jerome Pagani; Károly Markó; Ian McClain-Caldwell; Lynn Vitale-Cross; W Scott Young; Michael J Brownstein; Éva Mezey
Journal:  Sci Transl Med       Date:  2017-11-29       Impact factor: 17.956

6.  The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

Authors:  Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Régent Laporte; Halina Wiśniewska; Lillian D Traber; ChiiDean Lin; Juanjuan Fan; Hal K Hawkins; Robert A Cox; Kazimierz Wiśniewski; Claudio D Schteingart; Donald W Landry; Pierre J-M Rivière; Daniel L Traber
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

Review 7.  Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

Authors:  B Mouillac; M Manning; T Durroux
Journal:  Mini Rev Med Chem       Date:  2008-09       Impact factor: 3.862

8.  Anti-apoptotic actions of vasopressin in H32 neurons involve MAP kinase transactivation and Bad phosphorylation.

Authors:  Jun Chen; Simona Volpi; Greti Aguilera
Journal:  Exp Neurol       Date:  2008-03-10       Impact factor: 5.330

9.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.

Authors:  Rafik Marir; Anne Virsolvy; Kazimierz Wisniewski; Julie Mion; Dominique Haddou; Evelyne Galibert; Zahia Meraihi; Michel G Desarménien; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 10.  Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.

Authors:  Mahjabin Khan; Tao Huang; Cheng-Yuan Lin; Jiang Wu; Bao-Min Fan; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2017-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.